Here’s Who Picked Nivalis Therapeutics Inc. (NASDAQ:NVLS) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Nivalis Therapeutics Inc. (NASDAQ:NVLS) reported that Flynn James E has picked up 3,732,414 of common stock as of 2017-04-25.
The acquisition brings the aggregate amount owned by Flynn James E to a total of 3,732,414 representing less than 23.84% stake in the company.
For those not familiar with the company, Nivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company’s S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company’s lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR.
A glance at Nivalis Therapeutics Inc. (NASDAQ:NVLS)’s key stats reveals a current market capitalization of 30.58 Million based on 15.66 Million shares outstanding and a price at last close of $2.10 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-02, Carruthers picked up 24,000 at a purchase price of $2.09. This brings their total holding to 24,000 as of the date of the filing.
On the sell side, the most recent transaction saw Rodman unload 6,687 shares at a sale price of 2.27. This brings their total holding to 11,368.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Nivalis Therapeutics Inc. (NASDAQ:NVLS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Ronin Capital, Llc is Buying Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) reported that Ronin Capital, Llc. has picked up 95,059 of common stock as of 2017-04-17.
The acquisition brings the aggregate amount owned by Ronin Capital, Llc. to a total of 95,059 representing approximately 5.8% stake in the company.
For those not familiar with the company, Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.
A glance at Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM)’s key stats reveals a current market capitalization of 158.77 Million based on 297.71 Million shares outstanding and a price at last close of 0.546 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2012-03-14, Swartz picked up 16,000 at a purchase price of $0.62. This brings their total holding to 126,000 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Neos Therapeutics Inc. (NASDAQ:NEOS) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Neos Therapeutics Inc. (NASDAQ:NEOS) reported that Dammeyer Rodney F has picked up 1,001,568 of common stock as of 2017-04-14.
The acquisition brings the aggregate amount owned by Dammeyer Rodney F to a total of 1,001,568 representing a 6.2% stake in the company.
For those not familiar with the company, Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
A glance at Neos Therapeutics Inc. (NASDAQ:NEOS)’s key stats reveals a current market capitalization of 152.29 Million based on 22.56 Million shares outstanding and a price at last close of $6.80 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-08-31, Fong picked up 1,500 at a purchase price of $6.54. This brings their total holding to 1,500 as of the date of the filing.
On the sell side, the most recent transaction saw Presidio unload 213 shares at a sale price of $9.88. This brings their total holding to 39,998.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Neos Therapeutics Inc. (NASDAQ:NEOS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Lytton Laurence is Buying Catalyst Biosciences (NASDAQ:CBIO) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Catalyst Biosciences Inc. (NASDAQ:CBIO) reported that Lytton Laurence W has picked up 220,500 of common stock as of 2017-04-13.
The acquisition brings the aggregate amount owned by Lytton Laurence W to a total of 220,500 representing a 8.1% stake in the company.
For those not familiar with the company, Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
A glance at Catalyst Biosciences Inc. (NASDAQ:CBIO)’s key stats reveals a current market capitalization of 5.00 Million based on 1.00 Million shares outstanding and a price at last close of $5.41 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-12-17, Usman picked up 4,000 at a purchase price of $2.00. This brings their total holding to 78,375 as of the date of the filing.
On the sell side, the most recent transaction saw Barris unload 1,000 shares at a sale price of $5.13. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Catalyst Biosciences Inc. (NASDAQ:CBIO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
See who picked Bellicum Pharmaceuticals (NASDAQ:BLCM)
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) reported that Baker Bros. Advisors has picked up 5,032,313 of common stock as of 2017-04-11.
The acquisition brings the aggregate amount owned by Baker Bros. Advisors to a total of 5,032,313 representing a 15.2% stake in the company.
For those not familiar with the company, Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-601 and BPX-701. The Company’s CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
A glance at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM)’s key stats reveals a current market capitalization of 457.66 Million based on 32.16 Million shares outstanding and a price at last close of $12.86 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-24, Baker picked up 151,177 at a purchase price of $12.00. This brings their total holding to 4,527,089 as of the date of the filing.
On the sell side, the most recent transaction saw Slawin unload 30,000 shares at a sale price of $12.54. This brings their total holding to 294,982.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Mylan N.v. (NASDAQ:MYL) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Mylan N.v. (NASDAQ:MYL), reported that Abbott Laboratories has picked up 25,750,000 of common stock as of 2017-03-24.
The acquisition brings the aggregate amount owned by Abbott Laboratories to a total of 25,750,000 representing a 4.81% stake in the company.
For those not familiar with the company, Mylan is a global healthcare company focused on making high quality medicines available to everyone who needs them. Its heritage of being a provider of generic pharmaceuticals goes back to its founding in West Virginia in 1961. Today, Mylan is passionate champions for better health around the world with a platform unmatched in the industry. They have one of the broadest and most diverse portfolios, with more than 7,500 marketed products that include prescription generic and brand-name medicines, and consumer healthcare products. Their healthcare services help patients to access products and adhere to medication regimens to help promote better health outcomes.
A glance at Mylan N.v. (NASDAQ:MYL)’s key stats reveals a current market capitalization of 22.33 Billion based on 535.50 Million shares outstanding and a price at last close of $41.60 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-06-03 Maroon picked up 1,670 at a purchase price of $44.95. This brings their total holding to 22,036 as of the date of the filing.
On the sell side, the most recent transaction saw Abbott unload 44,000,000 shares at a sale price of $41.60. This brings their total holding to 25,750,000.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Mylan N.v. (NASDAQ:MYL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
True Nature Holding Inc. (OTCMKTS:TNTY) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), True Nature Holding Inc. (OTCMKTS:TNTY) reported that Lightmas Frank A. Jr. has picked up 1,052,857 of common stock as of 2017-03-14.
The acquisition brings the aggregate amount owned by Lightmas Frank A. Jr. to a total of 1,052,857 representing a 6% stake in the company.
For those not familiar with the company, True Nature Holding, Inc., formerly Trunity Holdings, Inc., is a development-stage company. The Company is focused on business of the production and sale of pharmaceutical products, including specialized compounded pharmaceutical formulations, for both the human and veterinary markets. The Company intends to acquire a series of businesses, which specialize in compounding pharmacy activities, direct to consumers, doctors and veterinary professionals. The Company is focused on selling its formulations primarily through a network of compounding pharmacies. The Company was engaged in educational business. As of December 31, 2015, the Company had not generated any revenues.
A glance at True Nature Holding Inc. (OTCMKTS:TNTY)’s key stats reveals a current market capitalization of 9.21 Million based on 17.21 Million shares outstanding and a price at last close of $0.535 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-07-01, Crone picked up 56,835 at a purchase price of $0.80. This brings their total holding to 156,835 as of the date of the filing.
On the sell side, the most recent transaction saw Baehren unload 11,137 shares at a sale price of $19.49. This brings their total holding to 62,760.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on True Nature Holding Inc. (OTCMKTS:TNTY) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Optimizerx Corp (OTCMKTS:OPRX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Optimizerx Corp (OTCMKTS:OPRX) reported that Wolverine Asset Management Llc. has picked up 2,155,860 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by Wolverine Asset Management Llc. to a total of 2,155,860 representing a 7.3% stake in the company.
For those not familiar with the company, OptimizeRx Corporation is a technology solutions company. The Company focuses on the healthcare industry. The Company connects patients, physicians and pharmaceutical manufacturers through technology. The Company’s solutions provide pharmaceutical manufacturers a direct to physician channel for communicating and promoting products. It provides healthcare providers a means to provide sampling and coupons without having to physically store samples on site. The Company’s principal products and applications include SampleMD, OPTIMIZEHR and OPTIMIZERx.com. SampleMD is a virtual Patient Support Center. OPTIMIZEHR is a consulting practice focused on educating and working with pharmaceutical manufacturers on identifying, formulating and implementing new electronic prescribing (eRx) media strategies for promoting their products. OPTIMIZERx.com is a portal to healthcare savings for patients to centrally review and participate in prescription and healthcare savings and support programs.
A glance at Optimizerx Corp (OTCMKTS:OPRX)’s key stats reveals a current market capitalization of 23.84 million based on 29.67 Million shares outstanding and a price at last close of $0.750 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-13, Pinney picked up 4,000 at a purchase price of $0.80. This brings their total holding to 781,079 as of the date of the filing.
On the sell side, the most recent transaction saw Radoff unload 631,100 shares at a sale price of $1.41. This brings their total holding to 2,289,200.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Optimizerx Corp (OTCMKTS:OPRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.